NICE technology appraisals
Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.
NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.
What NICE decided
Appraisals by recommendation type- Recommended: the NHS in England should fund it for the use it is licensed for.
- Optimised: recommended, but for a narrower group of patients than the licence covers.
- Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
- Only in research: to be used only as part of a study.
- Not recommended: NICE decided the NHS should not fund it for this use.
- Terminated: the company did not send evidence, so NICE could not make a recommendation.
An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.
Appraisals matching “Brentuximab Vedotin”
6 appraisals, newest first| Appraisal | Medicine page | NICE recommendation | Published | Status |
|---|---|---|---|---|
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma NICE TA1059 | Brentuximab Vedotin | Recommended | 7 May 2025 | Current |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma NICE TA641 | Brentuximab Vedotin | Recommended | 12 Aug 2020 | Current |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma NICE TA577 | Brentuximab Vedotin | Optimised | 24 Apr 2019 | Current |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma NICE TA524 | Brentuximab Vedotin | Optimised | 13 Jun 2018 | Current |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma NICE TA478 | Brentuximab Vedotin | Optimised | 4 Oct 2017 | Current |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma NICE TA446 | Brentuximab Vedotin | Optimised Optimised (Cancer Drugs Fund) | 28 Jun 2017 | Current |
Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.
© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
How this page is built
NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.
- NICE technology appraisal guidance ↗ appraisal titles, dates and status, from each appraisal page
- NICE technology appraisal recommendations data ↗ NICE's categorisation of every recommendation
A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 13 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.